Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

20150288 A Phase 2 Open-label Study Investigating the Safety and Efficacy of Blinatumomab After Frontline R-Chemotherapy in Adult Subjects With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma (DLBCL)

Next Previous
Trial Profile

20150288 A Phase 2 Open-label Study Investigating the Safety and Efficacy of Blinatumomab After Frontline R-Chemotherapy in Adult Subjects With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma (DLBCL)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Blinatumomab (Primary) ; Cyclophosphamide; Dexamethasone; Doxorubicin; Prednisone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions
  • Sponsors Amgen

Most Recent Events

  • 01 Sep 2022 Results of consolidation with blinatumomab in patients with newly diagnosed high-risk DLBCL,published in the Leukemia and Lymphoma
  • 12 Mar 2020 Cyclophosphamide, Dexamethasone, Doxorubicin, Prednisone, Rituximab, Vincristine have been officially added to the treatments section as a part of the study protocol. A safety follow-up for 30 days and a long-term follow-up of up to 8 months for a maximum 1 year have been introduced into the study.
  • 06 Nov 2019 Results assessing efficacy and safety of blinatumomab after first line rituximab chemotherapy for patients with newly diagnosed, released in 61st Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top